Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.
about
Electrocardiographic Changes and Arrhythmia in Fabry DiseaseThe cardiac conduction systemDefective Tbx2-dependent patterning of the atrioventricular canal myocardium causes accessory pathway formation in miceThe Genetic Challenges and Opportunities in Advanced Heart FailurePRKAG2 mutation: An easily missed cardiac specific non-lysosomal glycogenosis.Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies.Reversible transition from a hypertrophic to a dilated cardiomyopathy.Origin and development of the atrioventricular myocardial lineage: insight into the development of accessory pathways.AMP-activated protein kinase regulation and biological actions in the heart.AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease.Misinterpretation of the mouse ECG: 'musing the waves of Mus musculus'.Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy.Animal Models to Study AMPK.Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosisThe history of the wolff-Parkinson-white syndromeCardiac manifestations of PRKAG2 mutation.European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca yThe PRKAG2 gene and hypertrophic cardiomyopathy: an energetically imbalanced relationship.
P2860
Q26751508-EE3FC3CD-5F80-4201-B75E-F21F4377E574Q28116242-536FCA18-7943-4194-A035-217CD44C6342Q30497991-ECE6BE42-CD67-4286-8638-F346956E4A53Q33653498-511CCAE8-4163-431A-94DB-BE3B70B96B2EQ35676842-86109918-09FD-4010-81BB-28D196443AC3Q36458794-B244C499-BBA1-4585-A3FC-17F74A9832F8Q37340481-9D9FADCD-97E9-4CAB-A458-AE1E81667E87Q37883250-229B1C99-46C8-4432-8737-40D5B6262846Q38039283-41F9AE4D-0500-4ECD-9921-49E5F3A7D7DBQ38211516-57D353BD-322D-425B-9701-AE30D482C169Q38254729-FFAD9600-049D-4AF7-AFF6-4DAC7D0D13FEQ38399909-5FF1FB07-9E72-4350-92F8-BA09295BC0ACQ38998435-798F6A6E-D842-440D-8FD1-8F8558FE4D75Q40602766-D47AFBC4-76E5-4FCD-8F6F-2ADB874524EDQ42124714-C624D788-6658-4274-A902-1C414BC15BB6Q42149407-6A64D128-3230-4653-9E8C-C91360514020Q47119053-162BA416-4442-42FA-9B24-E984B539805DQ48032949-D74B0DDE-BCDF-4170-9AE9-611A332E9742Q48261584-45F13B9F-3C71-4756-A34E-90C29A0E4FD0
P2860
Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@ast
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@en
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@nl
type
label
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@ast
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@en
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@nl
prefLabel
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@ast
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@en
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@nl
P2093
P2860
P1433
P1476
Reversibility of PRKAG2 glycog ...... ophysiological manifestations.
@en
P2093
Atsushi Sanbe
Charles I Berul
Christine E Seidman
Cordula M Wolf
Ferhaan Ahmad
Gregory Morley
J G Seidman
Jeffrey Robbins
Michael Arad
P2860
P304
P356
10.1161/CIRCULATIONAHA.107.726752
P407
P577
2007-12-24T00:00:00Z